Forte Biosciences announced a definitive agreement to be acquired by argenx for $77.00 per share in cash via a tender offer followed by a merger, leaving Forte as a wholly owned subsidiary. The offer is subject to a majority tender, regulatory approvals, and other customary conditions, with no fina…
July 27, 2026 – 7:00 AM CETAmsterdam, the Netherlands and Dallas, Texas – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. NASDAQ:FBRX today announced that the companies have entered into a definitive agreement under which argenx will acquire Fo…
Shares of First Tracks Biotherapeutics Inc. (TRAX) hit an all-time high on Friday, after analysts cited positive clinical results from competitor Forte Biosciences Inc. (FBRX) as supportive of the broader drug class targeted by both companies.According to TheFly, HC Wainwright raised its price targ…
